Health
AstraZeneca's Tagrisso® and Calquence® Among First Oncology Treatments Granted Accelerated Access Through Ontario's FAST Program
AstraZeneca Canada is pleased to announce that Tagrisso® (osimertinib) and Calquence® (acalabrutinib tablets) are now publicly funded in Ontario and are among the first therapies to receive accelerated access through the province's new Funding Accelerated for Specific Treatments (FAST) program. With the introduction of FAST, the Government of Ontario has taken a significant step toward accelerating access to cancer medicines – demonstrating its commitment to putting patients first and embracing
About this update from Astrazeneca Plc
[{"type":"text","content":"Ontario is the first province to fund Tagrisso for patients with non-small cell lung cancer, and Calquence for patients with previously untreated mantle cell lymphoma ","length":166,"tagName":"p","attribs":{}},{"type":"text","content":"MISSISSAUGA, ON, Jan. 23, 2026 /CNW/ - AstraZeneca Canada is pleased to announce that Tagrisso® (osimertinib) and Calquence® (acalabrutinib tablets) are now publicly funded in Ontario and are among the first therapies to receive accelerated access through the province's new Funding Accelerated for Specific Treatments (FAST) program. With the introduction of FAST, the Government of Ontario has taken a significant step toward accelerating access to cancer medicines – demonstrating its commitment to putting patients first and embracing innovation so that life-changing treatments can reach those who need them, faster than ever.","length":650,"tagName":"p"},{"type":"image","alt":"AstraZeneca. (CNW Group/AstraZeneca Canada Inc.)","displaySize":"","headline":null,"caption":"AstraZeneca. (CNW Group/AstraZeneca Canada Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":121,"url":"https://media.zenfs.com/en/cnwgroup.com/135be03fa48bc770b4e56ab384d2c15b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bDbc4tNuWSarPREH0xszbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/135be03fa48bc770b4e56ab384d2c15b","width":400,"height":121}},"href":"https://mma.prnewswire.com/media/2867652/AstraZeneca_Canada_Inc__AstraZeneca_s_Tagrisso__and_Calquence__A.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""For every Ontarian facing a cancer diagnosis, timely access to high-quality treatment can make all the difference," said Sylvia Jones, Deputy Premier and Minister of Health. "Through the FAST program, our government is accelerating access to life-saving therapies including, Tagrisso and Calquence, bringing hope, peace of mind, and transformative care to those who need it most."","length":401,"tagName":"p"},{"type":"text","content":"Following recent positive reimbursement recommendations from the Canadian Drug Agency (CDA-AMC), Tagrisso is publicly reimbursed in Ontario for the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSC...